Background {#Sec1}
==========

Gram negative bacteria are responsible for a significant number of infections associated with health care in the pediatric population, especially *Klebsiella pneumoniae*, *Escherichia coli* and *Pseudomonas aeruginosa* \[[@CR1]\].

The carbapenems are considered the last resort antibiotics used for infections caused by multi-resistant Gram-negative bacilli, due to their stability against beta-lactamases penicillinases and cephalosporinases, and their broad spectrum of action \[[@CR2]\]. Additionally, carbapenems are often the only option in the treatment of severe infections due to the side effects of other antibiotics in the pediatric population \[[@CR1]\].

In recent years, frequent use of carbapenems has led to the emergence of resistance mechanisms, mediated primarily by enzymes called carbapenemases \[[@CR3], [@CR4]\]. These enzymes are found in mobile genetic elements which afford their dissemination and further limit treatment options, because they often harbor mechanisms of resistance to other antibiotics such as fluoroquinolones and aminoglycosides, necessitating the use of highly toxic antibiotics such as colistin \[[@CR3], [@CR4]\].

The clinical impact of carbapenem resistance has become a public health problem around the world in terms of increased mortality, longer hospital stays, and higher costs \[[@CR5]\]. The child population in this issue is of great concern as it is a naturally vulnerable population in which the risk may vary, depending on immunological maturity, the presence of comorbidities, the presence of invasive medical devices, and even the prior use of antibiotics \[[@CR6], [@CR7]\].

In Colombia, the rates of carbapenem-resistant Gram-negative bacilli have increased significantly in recent years. *Klebsiella pneumoniae* cabapenemase (KPC) has been frequently reported in Enterobacteriaceae and have started to be reported in *Pseudomonas aeruginosa* isolates, leading to KPC being considered endemic in the country \[[@CR8], [@CR9]\]. Additionally, outbreaks of NDM carbapenemase isolates, often associated with high levels of resistance to carbapenems and other β-lactams, have been reported in neonatal intensive care units \[[@CR10]\].

The behavior of infections caused by carbapenem- resistant bacteria has been studied in adults \[[@CR11], [@CR12]\]. However, despite the serious situation, very little is known about the difference in the behavior of infections caused by carbapenem-resistant bacteria in the pediatric population to that of infections reported in the adult population \[[@CR1], [@CR13], [@CR14]\].

The aim of this study, therefore, was to describe the clinical and molecular characteristics of infections caused by carbapenem-resistant Gram-negative bacilli in hospitalized children from five tertiary care institutions in Medellín, Colombia.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A cross-sectional study was conducted at five tertiary care hospitals located in Medellín, Colombia, from June 2012 to June 2014. Hospitals A and E are large university hospitals of 754 and 700 beds respectively, while hospitals B and C are medium-size tertiary care institutions (286 and 300 beds respectively), and hospital D is a 140-bed cardiology hospital. All patients under 15 years old and infected by carbapenem non-susceptible *Pseudomonas aeruginosa, Klebsiella pneumoniae*, *Enterobacter cloacae* or *Acinetobacter baumannii* were included \[[@CR15]\]. Microbiological and molecular analyses were performed on the first bacterial isolates recovered during hospitalization.

Clinical and epidemiological data {#Sec4}
---------------------------------

Both clinical and epidemiological information were obtained from the medical records of each patient. This information included sociodemographic characteristics, antimicrobial use, hospitalization and surgical history, intensive care unit (ICU) stay, type of infection, comorbidities, treatment and outcomes such as therapeutic failure, cure, and death. Infections were classified as either community or healthcare associated, according to standard epidemiological definitions established by the U.S. Centers for Disease Control and Prevention (CDC) \[[@CR16]\].

Bacterial identification and antibiotic susceptibility {#Sec5}
------------------------------------------------------

Identification of isolates and their antibiotic susceptibilities were carried out with the Vitek 2 automated system (BioMérieux, Marcy l'Etoile, France), according to CLSI \[[@CR15]\].

Detection of carbapenemasas and molecular typing {#Sec6}
------------------------------------------------

The presence of carbapenemases was evaluated through PCR amplification of genes *bla*~KPC~, *bla*~VIM~, *bla*~IMP~, *bla*~NDM~ and *bla*~OXA-48~, using previously described primers and conditions \[[@CR17], [@CR18]\]. After PCR amplification, forward and reverse sequencing was performed. Sequences were compared with those available at GenBank ([www.ncbi.nlm.nih.gov/blast/](http://www.ncbi.nlm.nih.gov/blast/)) and Lahey database (<http://www.lahey.org/Studies/>).

Pulse-field gel electrophoresis (PFGE) was performed using 50 U of *Spe*I, 20 U of *Xba*I and 50 U *Xba*I restriction enzime (Thermo Scientific, United States) for *P. aeruginosa, K. pneumoniae* and *E. cloacae,* respectively. DNA fragment patterns were normalized using the bacteriophage Lambda ladder PFGE marker (New England Biolabs, UK). Electrophoresis was performed on a CHEF DR III (Bio-Rad Laboratories, Hercules, CA) at 11 °C, angle 120° and voltage gradient 6 V/cm. Cluster analysis was performed using the Dice coefficient in BioNumerics software version 6.0 (Applied Maths, Sint-Martens-Latem, Belgium). Dendrograms were generated by the unweighted pair group method using average linkages (UPGMA), with 1 % tolerance and 0.5 % optimization settings. A similarity cutoff of ≥80 % was used to define genetically related strains.

Multilocus sequence typing (MLST) was performed using the methodology previously described on a subset of isolates representing the most frequent PFGE patterns in *P. aeruginosa* and *K. pneumoniae* \[[@CR19], [@CR20]\]. Allele numbers and sequence types (ST) were assigned using the database maintained at <http://pubmlst.org/paeruginosa/> and <http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html>.

Statistical analyses {#Sec7}
--------------------

Categorical variables were described using absolute and relative frequencies. Median and interquartile range or mean and standard deviation were used for continuous variables, according to data distribution. Statistical analyses were carried out using the software package SPSS® v20.0 (SPSS Inc., Chicago, USA).

Results {#Sec8}
=======

Clinical and epidemiological characteristics {#Sec9}
--------------------------------------------

Of a total about 673 pediatric patients infected by *K. pneumoniae, E. cloacae, P. aeruginosa* and *A. baumannii* during the study period, 59 (8.8 %) were infected by carbapenem-resistant isolates and were included in this report; most of them male (55.9 %; *n* = 33) and less than 1 year old (40.7 %; *n* = 24).

*Klebsiella pneumoniae* was found to be the most frequent cause of infection in the study population (47.4 %, *n* = 28), followed by *E. cloacae* and *P. aeruginosa* (40.7 %, *n* = 24 and 11.9 %, *n* = 7; respectively). No patients infected with *A. baumannii* were observed. Hospital A contributed the largest number of cases (40.7 %; *n* = 24), followed by Hospital B (27.1 %; *n* = 16) and Hospital C (18.6 %; *n* = 11). However, *P. aeruginosa* was predominant in Hospital A (66.7 %; *n* = 16), while *K. pneumoniae* was more frequent in hospital B (39.3 % *n* = 11).

Ninety-seven percent (*n* = 57) of infections were classified as health care associated according to CDC criteria after individual assessment of cases. The most common infections were urinary tract infections (45.8 %; *n* = 27), of which 15.5 % (*n* = 9) were associated to use of urinary catheters. At the time of sample collection, 42.4 % (*n* = 25) of patients were hospitalized in the intensive care unit (ICU) and 78 % (*n* = 46) had had invasive medical device procedures, such as central venous catheters (*n* = 29), internal nutrition probes (*n* = 28), urinary catheters (*n* = 20) and mechanical ventilation (*n* = 17) (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and clinical characteristics of patients infected by carbapenem resistant Gram-negative bacilliCharacteristicTotal*Pseudomonas aeruginosaKlebsiella pneumoniaeEnterobacter cloacae*No. (%)No. (%)No. (%)No. (%)Gender Male33 (55.9)16 (66.7)13 (46.4)4 (57.1) Female26 (44.1)8 (33.3)15 (53.6)3 (42.9)Age (yrs)  \< 124 (40.7)8 (33.3)12 (42.8)4 (57.1) 1 a 413 (20.0)6 (25.0)7 (25.0)0 5 a 813 (20.0)5 (20.8)6 (21.4)2 (28.6) 9 a 126 (10.2)3 (12.5)2 (7.1)1 (14.3)  \> 123 (5.1)2 (8.3)1 (3.6)0Hospital stay (days) Me (RI)37 (16--76)33 (15--70)48 (25--77)29 (10--33)Hospital A24 (40.7)16 (66.7)5 (17.9)3 (42.9) B16 (27.1)2 (8.3)11 (39.3)3 (42.9) C11 (18.6)3 (12.5)7 (25.0)1 (14.3) D7 (11.9)3 (12.5)4 (14.3)0 E1 (1.7)01 (3.6)0History in past 6 months Hospitalization44 (74.6)15 (62.5)25 (89.3)4 (57.1) Surgery37 (62.7)15 (62.5)19 (67.9)3 (42.9) Stay in ICU30 (50.8)13 (54.2)15 (53.6)2 (28.6) Immunosuppressive therapy16 (27.1)8 (33.3)6 (21.4)2 (28.6) Dialysis8 (13.56)3 (12.5)5 (17.9)0Antimicrobial use in past56 (94.9)23 (95.8)27 (96.4)6 (85.7) Carbapenems22 (37.3)7 (29.2)13 (46.4)2 (28.6) Piperacillin-tazobactam22 (37.3)3 (12.5)15 (53.6)4 (57.1) Glycopeptides18 (30.5)7 (29.2)10 (35.7)1 (14.3) 1st-generation cephalosporin17 (28.8)6 (25.0)8 (28.6)3 (42.9) Aminoglycosides13 (22.0)5 (20.8)8 (28.6)0 4th-generation cephalosporin10 (16.9)3 (12.5)6 (21.4)1 (14.3) Penicillin9 (15.3)5 (20.8)3 (10.7)1 (14.3) Fluoroquinolones9 (15.3)07 (25.0)2 (28.6) 3rd-generation cephalosporin8 (13.6)6 (25.0)2 (7.1)0 TMP-SMX7 (11.9)2 (8.3)5 (17.9)0 Macrolides2 (3.4)2 (8.3)00 Lincosamides2 (3.4)02 (7.1)0 Oxazolidinones2 (3.4)02 (7.1)0 2nd-generation cephalosporin1 (1.7)1 (4.2)00 Colistin1 (1.7)01 (3.6)0 Monobactams1 (1.7)01 (3.6)0 Lipopeptides1 (1.7)1 (4.2)00Infection type Health care associated57 (96.6)23 (95.8)28 (100)6 (85.7) Community associated2 (3.4)1 (4.2)01 (14.3)Hospitalization in ICU at time of isolate25 (42.4)10 (41.7)12 (42.9)3 (42.9)Medical device46 (78.0)20 (83.3)20 (71.4)6 (85.7) Central venous catheter29 (49.2)12 (50.0)14 (50.0)3 (42.9) Enteral nutrition28 (47.5)12 (50.0)12 (42.9)4 (57.1) Urinary catheter20 (33.9)6 (25.0)12 (42.9)2 (28.6) Invasive mechanical ventilation17 (28.8)9 (37.5)6 (21.4)2 (28.6) Parenteral nutrition8 (13.6)3 (12.5)5 (17.9)0Comorbidities56 (94.9)22 (91.7)28 (100.0)6 (85.7) Cardiovascular disease12 (20.3)4 (16.7)7 (25.0)1 (14.3) Neurologic disease7 (11.9)3 (12.5)3 (10.7)1 (14.3) Lung disease6 (10.2)3 (12.5)1 (3.6)2 (28.6) Chronic renal disease5 (8.5)4 (16.7)1 (3.6)0 Transplant5 (8.5)2 (8.3)2 (7.1)1 (14.3) Trauma3 (5.1)1 (4.2)2 (7.1)0 Burns3 (5.1)2 (8.3)1 (3.6)0 Cancer2 (3.4)02 (7.1)0 Leukemia2 (3.4)1 (4.2)1 (3.6)0 Cystic fibrosis1 (1.7)1 (4.2)00 Immunosuppression1 (1.7)1 (4.2)00Infection site Urinary tract infection (UTI)18 (31)5 (20.8)10 (37.0)3 (42.9) Catheter-associated UTI9 (15.5)3 (12.5)6 (22.2)0 Ventilator-associated pneumonia7 (12.2)2 (8.3)3 (11.1)2 (28.6) Bloodstream6 (10.3)1 (4.2)4 (14.8)1 (14.3) Pneumonia6 (10.3)5 (20.8)1 (3.7)0 Catheter-related bloodstream3 (5.2)2 (8.3)1 (3.7)0 Skin and soft tissue2 (3.4)2 (8.3)00 Surgical site1 (1.7)001 (14.3) Intra-abdominal1 (1.7)01 (3.7)0Empirical therapy51 (86.4)19 (79.2)25 (89.3)7 (100.0) Carbapenems16 (27.1)4 (16.7)11 (39.3)1 (14.3) Piperacilin-tazobactam16 (27.1)7 (29.2)6 (21.4)3 (42.9) Glycopeptides13 (22)6 (25.0)5 (17.9)2 (28.6) Aminoglycosides13 (22)2 (8.3)9 (32.1)2 (28.6) 4th-generation cephalosporin7 (11.9)4 (16.7)1 (3.6)2 (28.6) Fluoroquinolones3 (5.1)1 (4.2)2 (7.1)0 Monobactams2 (3.4)2 (8.3)00 3rd-generation cephalosporin2 (3.4)2 (8.3)00 1st-generation cephalosporin1 (1.7)0 (0)1 (3.6)0 Penicillin1 (1.7)001 (14.3) Oxazolidinones1 (1.7)01 (3.6)0 TMP-SMX1 (1.7)01 (3.6)0 Colistin1 (1.7)01 (3.6)0Targeted therapy53 (89.8)20 (83.3)27 (96.4)6 (85.7) Colistin16 (27.1)2 (8.3)14 (50.0)0 Aminoglycosides16 (27.1)6 (25.0)9 (32.1)1 (14.3) Carbapenems14 (23.7)3 (12.5)10 (35.7)1 (14.3) Fluoroquinolones10 (16.9)6 (25.0)3 (10.7)1 (14.3) 4th-generation cephalosporin9 (15.3)5 (20.8)2 (7.1)2 (28.6) Piperacilin-tazobactam4 (6.8)3 (12.5)01 (14.3) Monobactams2 (3.4)1 (4.2)1 (3.6)0 3rd-generation cephalosporin2 (3.4)2 (8.3)00 Glycopeptides1 (1.7)01 (3.6)0 Oxazolidinones1 (1.7)01 (3.6)0 TMP-SMX1 (1.7)01 (3.6)0Surgical Treatment6 (10.2)3 (12.5)3 (10.7)0Outcome Cure38 (69.1)13 (59.1)20 (76.9)5 (71.4) Death9 (16.4)4 (18.2)4 (15.4)1 (14.3) Improvement7 (12.7)4 (18.2)2 (7.7)1 (14.3) Voluntary discharge1 (1.8)1 (4.5)00

The medical histories of patients revealed the presence of comorbidities and frequent use of antibiotic within the past 6 months (94.9 %, *n* = 56), mainly carbapenems and piperacillin / tazobactam (37.3 %; *n* = 22), which were also those most commonly used as empirical treatments. Likewise, a high percentage of patients with history of hospitalization (74.6 %; *n* = 44) and surgery during the previous six months (62.7 %; *n* = 37) were found, more so in the case of *K. pneumoniae* than other bacteria (Table [1](#Tab1){ref-type="table"}).

In the targeted therapy, the use of colistin is highlighted in the patients infected with *K. pneumoniae* (50 %; *n* = 14) and the use of aminoglycosides and fluoroquinolones of those infected with *P. aeruginosa* (25 %: *n* = 6).

The main outcome in the patients studied was cure (69.1 %; *n* = 38), however, all-cause mortality resulted in 16.4 % (*n* = 9) of cases. The median of hospital stay was higher for infections caused by *K. pneumoniae* (48 days) compared to those caused by *P. aeruginosa* and *E. cloacae* (33 and 29, respectively) (Table [1](#Tab1){ref-type="table"}).

Antibiotic susceptibility {#Sec10}
-------------------------

In *K. pneumoniae* isolates, high frequencies of ertapenem, imipenem and meropenem resistance were observed (94.1, 92, and 89.3 %, respectively). With the exception of amikacin and ciprofloxacin, the resistance rate to all antibiotics tested was over 70 %. In contrast, in *P. aeruginosa* and *E. cloacae* isolates, imipenem resistance was observed in 100 % of cases, and for other antibiotics, including meropenem and ertapenem, resistance was under 67 % (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Resistance percentages in carbapenem resistant Gram-negative bacilli

Carbapenemases detection and molecular typing {#Sec11}
---------------------------------------------

The presence of carbapenemases was observed mainly in isolates of *K. pneumoniae*, being 85.7 % (*n* = 24) positive for KPC carbapenemase, of which 21 contained KPC-2 and 3 KPC-3. For *P aeruginosa* and *E. cloacae*, most isolates were non-carbapenemase producing (87.5 %, *n* = 21 and 85.7 %; *n* = 6, respectively). Carbapenemase VIM-2 was found in three isolates of *P. aeruginosa*, and one isolate of *E. cloacae* was positive for KPC-3. Most *K. pneumoniae* isolates were closely related (Dice coefficient \> 82 %) and MLST revealed isolates belonged to ST14 (39.3 % *n* = 11). The isolates of *E. cloacae* and *P. aeruginosa* were highly diverse and the ST170 and ST1804 were found in *P. aeruginosa* (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Genetic relatedness of carbapenem resistant Gram-negative bacilli

Discussion {#Sec12}
==========

The present study describe clinical and molecular characteristics of infections caused by carbapenem-resistant Gram-negative bacilli in children and provided an overview in order to improve our understanding of the problem become in a matter of great concern.

In this study, the majority of infections were healthcare associated, which have had a significant worldwide increase, especially in children \[[@CR1], [@CR14], [@CR21], [@CR22]\]. Different studies have reported the relationship between the hospital environment and the presence of infections caused by resistant bacteria, which has been associated with mortality rates as high as 37 % in the pediatric population \[[@CR1], [@CR14], [@CR23]\]. These infections particularly affect children under one year old, a feature that was observed in this study and that can be explained by the immunological immaturity of infancy, which leads to neonatal patients being more susceptible \[[@CR23]--[@CR26]\].

In addition to the aforementioned, other factors that may facilitate infections by resistant bacteria are premature birth, low birth weight (associated with increased mortality), long hospital stays, the use of medical devices, underlying conditions, and previous contact with the hospital environment. These last three characteristics were frequently found in the patients included in this study \[[@CR1], [@CR6], [@CR14]\].

Of all healthcare-associated infections, urinary tract infection has been reported as one of the most frequent both in the pediatric population and in children under one year old. It was also the most commonly found infection in this study, though the results contrast with those reported in other studies in which the most frequently occurring infections are bacteremia and pneumonia \[[@CR1], [@CR23], [@CR25]\].

The proportion of catheter- associated urinary tract infections was 15 %, which shows the need to strengthen hand-hygiene, contact precautions and the replacement of invasive devices. Many of the outbreaks of infection caused by Gram-negative bacilli in neonatal and pediatric units have been the result of failures in these measures \[[@CR1], [@CR27]\]. Additionally, bacteria such as *K. pneumoniae* y *P. aeruginosa* have the ability to form biofilm, allowing them to adhere to different materials \[[@CR1], [@CR27]\].

Although bacteria-resistant infection rates are higher in ICU compared to other hospital wards, less than half of the patients in this study were hospitalized in this service, which shows the importance of epidemiological surveillance of these infections in wards other than ICU \[[@CR6], [@CR28]\].

Medical records show prior antibiotics use, predominantly carpabenems, in almost 95 % of patients in this study, which has been considered an independent risk factor for infections caused by resistant bacteria in both adults and children \[[@CR11], [@CR23], [@CR29], [@CR30]\]. These findings highlight the importance of establishing of antimicrobial stewardship programs as a strategy to control the spread of antibiotic-resistant bacteria in the pediatric population, and more importantly still, in neonatal and pediatric intensive care units where these medications are used the most frequently (55.8 %; 95 % CI: 50.3-61.3 %) \[[@CR31]\].

Additionally, the use of antibiotics at an early age not only encourages the evolution of resistant bacteria, but also changes the body microbiota, which in turn has been associated with subsequent infections and even with immune disorders such as asthma, and metabolic disorders such as obesity \[[@CR32]\]. This in turn heightens the risk of intestinal colonization by resistant bacteria, which in neonatal patients encourages the transmission of these microorganisms to their households after the hospitalization period \[[@CR33]\].

As has been reported in other studies, this investigation found *Klebsiella pneumoniae* to be the most frequently-occurring microorganism \[[@CR1], [@CR14], [@CR34]\]. For this bacteria the resistance mechanism observed in the majority of outbreaks was KPC, the enzyme encoded on mobile genetic elements such as transposon Tn4401, and which has been reported not only in the family Enterobacteriaceae, but also in non-fermetative bacilli such as *Pseudomonas aeruginosa* \[[@CR8], [@CR35], [@CR36]\]. These genetic elements may also harbor resistance determinants to other antibiotics classes, as was evident in the high resistance rates of *K. pneumoniae* isolates compared with *P. aeruginosa* and *E. cloacae*, which for the most part did not contain carbapenemases, and had a higher sensitivity to aminoglycosides and meropenem \[[@CR37], [@CR38]\]. Within the group of aminoglycosides, amikacin sensitivity was higher than gentamicin sensitivity in isolations of *K. pneumoniae* and *P. aeruginosa*, a previously-observed characteristic in carbapenem resistant strains found in children \[[@CR6]\].

It has been reported that the presence of carbapenemases such as KPC, further restricts the treatment that can be administered to pediatric patients because it limits therapeutic options not only within the beta-lactam groups, but also in other families of antibiotics \[[@CR6], [@CR39], [@CR40]\]. The result has been antimicrobials in monotherapy or in combinations for the treatment of these infections, which can be highly toxic and can cause serious side effects in still-growing patients \[[@CR39], [@CR40]\].

In this study, 28/59 carbapenem-resistant isolates were positive for carbapenemases. The remained isolates negative to these enzymes could harbor other mechanisms for carbapenem resistance, including overexpression of efflux systems as MexAB-OprM for *P. aeruginosa*, overexpression of AmpC or ESBL betalactamases combined with permeability alteration (deficient expression or loss of porins) in *K. pneumoniae, E. cloacae* and *P. aeruginosa* or other carbapenemases were not evaluated \[[@CR41], [@CR42]\].

Another significant finding was the presence of the *K. pneumoniae* ST14 clone as the main cause of infections in the patients of the study. Previous reports have suggested the importance of this clone in the pediatric population, particularly in infants and have described it as a high-risk clone, due to its ability to spread and host resistance determinants to beta-lactams, including ESBL such as CTX -M-15 and carbapenemases such as KPC and NDM-1 \[[@CR43]--[@CR46]\].

Although the carbapenem-resistant *K. pneumoniae* ST258 clone is more widespread worldwide and has been found in outbreaks in neonatal units, it was not found in this study, agreement with previous research in Italy and Colombia, which a high frequency of non -ST258 clones were described \[[@CR47], [@CR48]\]. Meanwhile, the high genetic variability observed in isolates of *P. aeruginosa* and *E. cloacae* show a high antibiotic pressure that is conducive to the presence of new clones such as ST1804, reported for the first time in Colombia \[[@CR8]\].

Finally, in this study there was not carbapenem-resistant *Acinetobacter baumannii* isolates, which is quite prevalent is other countries. Recent studies have shown a decrease in the frequency of resistant *A. baumannii* isolates in comparison with other multidrug-resistant Gram-negative bacilli causing infection in Colombia and particularly in Medellín \[[@CR21], [@CR49]\]. Likewise, a surveillance study conducted by our research group in five hospitals of Medellin, included only 32 carbapenem-resistant isolates during two years of study, showing the low frequency of this bacteria in our city \[[@CR50]\].

Conclusions {#Sec13}
===========

This study demonstrates an increase in the presence of Gram-negative carbapenem-resistant bacilli in the pediatric population, which has become a matter of serious concern. This mainly affects children less than 1 year old with underlying conditions, prior contact with the hospital environment, and a history of previous antibiotics use. It is important to conduct regular monitoring and establish stewardship programs of antibiotics to prevent the spread of resistant bacteria, which limit treatment options in a population particularly vulnerable to these infections.

ICU

:   Intensive care unit

KPC

:   *Klebsiella pneumoniae* cabapenemase

MLST

:   Multilocus sequence typing

PFGE

:   Pulse-field gel electrophoresis

ST

:   Sequence type

UPGMA

:   Unweighted pair group method using average linkages

UTI

:   Urinary tract infection
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